CDK
Gli inibitori delle chinasi ciclina-dipendenti (CDK) sono composti che bloccano l'attività delle CDK, un gruppo di chinasi proteiche che regolano il ciclo cellulare, la trascrizione e altri processi cellulari. Le CDK vengono attivate legandosi alle cicline e la loro attività è cruciale per la progressione delle cellule attraverso le diverse fasi del ciclo cellulare. Inibire le CDK può bloccare la divisione cellulare, portando all'arresto del ciclo cellulare e all'apoptosi, in particolare nelle cellule tumorali in cui le CDK sono spesso disregolate. Gli inibitori delle CDK sono ampiamente utilizzati nella ricerca sul cancro e hanno un potenziale terapeutico nel trattamento di vari tipi di cancro. Presso CymitQuimica, offriamo una selezione completa di inibitori delle CDK di alta qualità per supportare la tua ricerca sul controllo del ciclo cellulare, sul cancro e sullo sviluppo terapeutico.
Trovati 522 prodotti di "CDK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK9-IN-19
CAS:CDK9-IN-19: Potent CDK9 inhibitor, anti-cancer, moderate pharmacokinetics, low hERG impact, effective in AML research.Formula:C26H22F2N4O5Colore e forma:SolidPeso molecolare:508.475-Iodo-indirubin-3'-monoxime
CAS:5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50sFormula:C16H10IN3O2Colore e forma:SolidPeso molecolare:403.17CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Formula:C22H24F3N6OPColore e forma:SolidPeso molecolare:476.43DCB-3503
CAS:DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.Formula:C24H27NO5Colore e forma:SolidPeso molecolare:409.47Voruciclib hydrochloride
CAS:Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).Formula:C22H20Cl2F3NO5Purezza:98%Colore e forma:SolidPeso molecolare:506.3Inixaciclib
CAS:Inixaciclib is a potent CDK inhibitor, can be used to research anticancer.Formula:C26H30F2N6OColore e forma:SolidPeso molecolare:480.55KM05382
CAS:KM05382 inhibits CDK9 and the transcription of GAPDH.Formula:C20H19ClN2O3S2Colore e forma:SolidPeso molecolare:434.96Riviciclib
CAS:Riviciclib, a CDK inhibitor (CDK9/T1, CDK4/D1, CDK1/B), has IC50s: 20, 63, 79 nM respectively, and fights cisplatin-resistant tumors.Formula:C21H20ClNO5Purezza:98%Colore e forma:SolidPeso molecolare:401.84Cdk4 Inhibitor
CAS:PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.Formula:C20H10BrN3O2Colore e forma:SolidPeso molecolare:404.2CCT-251921
CAS:CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).Formula:C21H23ClN6OPurezza:99.07%Colore e forma:SolidPeso molecolare:410.9ML 315 hydrochloride
CAS:<p>ML 315, a selective dual inhibitor targeting CDK (Cyclin-Dependent Kinase) and DYRK (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase) with IC50 values of 68 nM and 282 nM, respectively, is utilized in research pertaining to cancer and neurological diseases [1].</p>Formula:C18H14Cl3N3O2Colore e forma:SolidPeso molecolare:410.682Senexin C
CAS:Senexin C is a CDK8/19 inhibitor with anticancer activity.Senexin C inhibits the growth of MV4-11 leukemia cells.Formula:C28H27N5OPurezza:98.06%Colore e forma:SolidPeso molecolare:449.55CDK7-IN-22
CAS:CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].Formula:C22H25F3N6Purezza:98%Colore e forma:SolidPeso molecolare:430.47CDK9-IN-23
CAS:CDK9-IN-23 (Example 4) is a potent inhibitor of CDK9, exhibiting an IC50 value of less than 20 nM [1].Formula:C22H25ClN4O3Purezza:98%Colore e forma:SolidPeso molecolare:428.91SHP2/CDK4-IN-1
CAS:SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.Formula:C33H35ClF2N10OSColore e forma:SolidPeso molecolare:693.21EHT 5372
CAS:EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.Formula:C17H11Cl2N5OSColore e forma:SolidPeso molecolare:404.27Leucettinib-92
CAS:Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μMFormula:C21H22N4OSPurezza:98%Colore e forma:SolidPeso molecolare:378.49CDK7-IN-25
CAS:CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].Formula:C33H32N6O3Purezza:98%Colore e forma:SolidPeso molecolare:560.65CDK4-IN-2
CAS:CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].Formula:C22H26F2N6O4SPurezza:98%Colore e forma:SolidPeso molecolare:508.54CF53
CAS:CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.Formula:C24H25N7O2Purezza:99.72%Colore e forma:SolidPeso molecolare:443.5
